Journal article
Evaluation of Circulating Glypican-4 in Patients with ESKD
Kidney360, v 6(6), pp 975-982
Jun 2025
PMID: 40063102
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Key PointsGlypican-4 (GPC4) levels were strongly elevated in incident dialysis patients compared with individuals without evidence of kidney disease.Circulating GPC4 was significantly correlated with various parameters linked to adverse conditions commonly present in incident dialysis patients.No association was found between GPC4 and all-cause mortality in incident dialysis patients.BackgroundGlypican-4 (GPC4) is a cell surface heparan sulfate proteoglycan that can be released into circulation under various clinical conditions. Elevated levels of circulating GPC4 have recently been associated with reduced kidney function and an increased risk of all-cause mortality across different patient populations. The potential of circulating GPC4 for assessing disease status or prognosis in patients with ESKD has not yet been explored and was addressed in this study.MethodsThis study included 187 patients starting chronic dialysis treatment. In addition, 108 control subjects with normal or mildly reduced kidney function, matched for sex and age, were included in the study. The median follow-up time of incident dialysis patients was 3.8 years. Blood samples were collected immediately before initiation of dialysis. Serum GPC4 levels were determined using an enzyme-linked immunosorbent assay.ResultsSerum GPC4 levels were approximately ten-fold higher in incident dialysis patients compared with controls, demonstrating excellent classification ability to distinguish between the two groups. Furthermore, circulating GPC4 was significantly positively correlated with creatinine and phosphate and significantly negatively correlated with estimated GFR, hemoglobin, erythrocytes, calcium, and cholinesterase in incident dialysis patients. There was no significant association between GPC4 levels and all-cause mortality in patients starting dialysis.ConclusionsGPC4 levels were markedly elevated in patients initiating dialysis and were linked with several pathophysiologic characteristics commonly observed in ESKD. However, our findings did not indicate that elevated serum GPC4 levels serve as a significant predictor of all-cause mortality in this patient population.
Metrics
1 Record Views
Details
- Title
- Evaluation of Circulating Glypican-4 in Patients with ESKD
- Creators
- Axel Muendlein - Vorarlberg Institute for Vascular Investigation and TreatmentEva Maria Brandtner - Vorarlberg Institute for Vascular Investigation and TreatmentJudith Schimpf - Landeskrankenhaus FeldkirchMichael Piribauer - Landeskrankenhaus FeldkirchKathrin Geiger - Vorarlberg Institute for Vascular Investigation and TreatmentChristine Heinzle - Vorarlberg Institute for Vascular Investigation and TreatmentAndreas Leiherer - Vorarlberg Institute for Vascular Investigation and TreatmentHeinz Drexel - Vorarlberg Institute for Vascular Investigation and TreatmentOtto Freistaetter - Vorarlberg Inst Vasc Invest & Treatment, Feldkirch, AustriaUlrich Neyer - Vorarlberg Institute for Vascular Investigation and TreatmentEmanuel Zitt - Landeskrankenhaus Feldkirch
- Publication Details
- Kidney360, v 6(6), pp 975-982
- Publisher
- American Society of Nephrology
- Number of pages
- 8
- Grant note
- State Government of Vorarlberg (Bregenz, Austria)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine
- Web of Science ID
- WOS:001516969500001
- Scopus ID
- 2-s2.0-105003416783
- Other Identifier
- 991022197301404721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
Source: SDGs in the Output
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- International collaboration
- Web of Science research areas
- Urology & Nephrology